Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles
Authors:
- 1 September 1991
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 41 (3) , 263-265
Abstract
Twenty-two NIDDM patients completed an open randomized cross-over study comparing metformin and glibenclamide over 1 year. The drugs had an equivalent effect on glycaemic control, but, in contrast to glibenclamide, metformin reduced body weight. Neither drug affected triglycerides, total-and LDL-cholesterol or C-peptide. Metformin caused a slight elevation of HDL-cholesterol (P < 0.05). No serious adverse effects were observed. The results show that oral hypoglycaemic agents are not associated with undesirable effects on lipids and lipoproteins.Keywords
This publication has 8 references indexed in Scilit:
- IntroductionDiabetes Care, 1990
- Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM PatientsDiabetes Care, 1990
- Oral Hypoglycemic AgentsNew England Journal of Medicine, 1989
- Lipids, Diabetes, and Vascular Disease: The Time to ActDiabetic Medicine, 1989
- The Reduction of Low Density Lipoprotein Cholesterol by Metformin is Maintained with Long-Term TherapyJournal of the Royal Society of Medicine, 1989
- The Effect of Glibenclamide and Metformin on Serum Lipoproteins in Type 2 DiabetesDiabetic Medicine, 1988
- Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese SubjectsThrombosis and Haemostasis, 1987
- A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in type 2 (non-insulin-dependent) diabetesDiabetologia, 1982